Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Results from the GOBLET study

Arnold, Dirk et al. Previously presented at ESMO Congress 2023, Oct. 23, 2023